Surims Ltd Logo
Grand River Aseptic Manufacturing (GRAM) Logo  

Grand River Aseptic Manufacturing (GRAM)


Add to My Companies | Give a Referral for this Company | Print this Profile
Basic Profile
If you'd like to claim this company profile for Grand River Aseptic Manufacturing (GRAM), please Contact Us.

Grand River Aseptic Manufacturing (GRAM) News

The latest news, announcements and press releases from Grand River Aseptic Manufacturing (GRAM).

08th April 2021

NEW Finishing & Warehouse Center for GRAM

To meet heightened customer demand, GRAM has embarked on another expansion!

Less than one year after the completion of our large-scale filling facility GRAM’s new finishing and warehouse expansion is underway, bringing our total number of GMP manufacturing facilities to four.

Read the full story »
30th September 2020

GRAM, J&J Enter COVID-19 Vax Manufacturing Pact

Grand River Aseptic Manufacturing (“GRAM”), a leading injectable contract development and manufacturing organization (CDMO), has entered into an agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to support the manufacture of its SARS-CoV-2 vaccine candidate.

The agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson’s SARS-CoV-2 vaccine candidate. Together, teams from both companies are working diligently to transfer the manufacturing process to GRAM’s new, state-of-the-art facility, and are swiftly preparing for the start of vaccine production.

“Should their vaccine candidate be approved, the opportunity to serve the population with a vaccine to combat the COVID-19 pandemic alongside Johnson & Johnson is an extraordinary privilege,” said Tom Ross, President and CEO of GRAM. “Our team is enthusiastic, dedicated and focused on supporting Johnson & Johnson in the fight against COVID-19.”

GRAM is expanding domestic fill/finish capacity for COVID-19 vaccines and therapeutics for companies that have agreements with the federal government to meet its Operation Warp Speed goals. The GRAM expansion is funded, in part, by the Biomedical Advanced Research and Development Authority (BARDA) part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in collaboration with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

Read the full story »
13th July 2020

With calls for American-made drugs on the rise, a Michigan CDMO is scaling up to meet demand

“Onshore” manufacturing has become a bit of a buzzword term in the age of COVID-19 as lawmakers push for a stable drug supply chain on U.S. soil. But for small CDMO Grand River Aseptic Manufacturing (GRAM), that made-in-America ethos is stamped in its DNA, and a brand-new finish-fill plant could help it target even more U.S. drugmakers.

Michigan-based GRAM completed a $60 million expansion to install a “large-scale” fill-finish injectables facility that it will market primarily to U.S drugmakers, the company said Tuesday.

The new 60,000-square-foot facility in downtown Grand Rapids will triple GRAM’s manufacturing footprint to more than 100,000 square feet of production space and help level up the company’s sterile injectables offerings, according to a release. The newest fill-finish plant is GRAM’s third, the company said, and its fifth manufacturing facility overall.

In its 10th year in business, GRAM has been able to afford its rapid scale-up through strong growth and its reputation as a high-quality manufacturing partner in the heart of the Midwest, CEO Tom Ross told Fierce Pharma.

GRAM plans to market its new manufacturing space to a stable of existing customers as well as drugmakers looking to “onshore” their manufacturing back on U.S. soil. That strategic direction stems from GRAM’s unique position as an American-made company but also a response to a growing need for domestic contract manufacturers.

“The ability to grow off the same base and focus the culture around quality and service is critical,” Ross said. “The opportunity is there for us to continue to meet that demand.”

Read the full story »

Claim This Profile

This is the News section of the company profile page for Grand River Aseptic Manufacturing (GRAM) on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.

Grand River Aseptic Manufacturing (GRAM) company details, activities, contacts and reviews.
Grand River Aseptic Manufacturing (GRAM) partnership and licensing opportunities.
Grand River Aseptic Manufacturing (GRAM) latest news, announcements and press releases.
Grand River Aseptic Manufacturing (GRAM) documents, images and videos.
Grand River Aseptic Manufacturing (GRAM) global factories, offices and locations.
Grand River Aseptic Manufacturing (GRAM) legal and financial information.

About Us

Surims Ltd is a consultancy established in 2003 supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own on-boarding and supplier management activities. Further information on our software services can be found at


Get in Touch

The Pharmaceutical Services Directory


© 2021 Surims Ltd | All Rights Reserved.